reboxetine + sertraline

Reboxetine + sertraline is a combination of two antidepressant drugs, reboxetine and sertraline, used together primarily in the management of major depressive disorder and treatment-resistant depression. Reboxetine is a selective norepinephrine reuptake inhibitor (NRI), while sertraline is a selective serotonin reuptake inhibitor (SSRI). The rationale for combining these agents is to achieve dual inhibition of both norepinephrine and serotonin reuptake, potentially enhancing antidepressant efficacy compared to monotherapy with either agent alone. This combination has been studied in clinical trials and preclinical models, showing improved outcomes in some cases over single-drug therapy[1][2][4][6][7]. The side effect profile generally reflects those of the individual drugs; however, careful monitoring for drug interactions and serotonergic toxicity is necessary.

Other names

sertraline + [s,s]-reboxetinesertraline and reboxetine combination